 Busulfan
"Busulfan" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
| Descriptor ID |
D002066
|
| MeSH Number(s) |
D02.033.455.125.125 D02.455.326.146.100.050.500.100 D02.886.645.600.055.050.510.100
|
| Concept/Terms |
Busulfan Wellcome- Busulfan Wellcome
- Wellcome, Busulfan
- Wellcome Brand of Busulfan
- Busulfan Wellcome Brand
Busulfex- Busulfex
- Orphan Brand of Busulfan
- Busulfan Orphan Brand
Myleran- Myleran
- Glaxo Wellcome Brand of Busulfan
- GlaxoSmithKline Brand of Busulfan
- Busulfan GlaxoSmithKline Brand
- Myléran
|
Below are MeSH descriptors whose meaning is more general than "Busulfan".
Below are MeSH descriptors whose meaning is more specific than "Busulfan".
This graph shows the total number of publications written about "Busulfan" by people in UAMS Profiles by year, and whether "Busulfan" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2019 | 2 | 0 | 2 | | 2018 | 1 | 0 | 1 | | 2014 | 2 | 0 | 2 | | 2010 | 1 | 1 | 2 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 2 | 3 | | 2006 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 1996 | 1 | 0 | 1 | | 1992 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Busulfan" by people in Profiles over the past ten years.
-
Boysen G, Shimoni A, Danylesko I, Varda-Bloom N, Nagler A. A simplified method for detection of N-terminal valine adducts in patients receiving treosulfan. Rapid Commun Mass Spectrom. 2019 Nov 15; 33(21):1635-1642.
-
Radhakrishnan SV, Boyer M, Sherwin CM, Zangari M, Tricot G. A Phase 1 Study of Intravenous Busulfan as a Conditioning Regimen for Multiple Myeloma. Cell Transplant. 2019 Dec; 28(12):1624-1631.
-
Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 04; 25(4):728-733.
-
Kanaji S, Fahs SA, Ware J, Montgomery RR, Shi Q. Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome. J Thromb Haemost. 2014 Oct; 12(10):1726-32.
-
Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E, Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S, Armstrong E, Smith A, Elekes A, Kato K, Reece DE. Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1949-57.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|